Why So Many Drugs Fail in Phase 2 & 3 | Jack Hidary at the Cures Conference @sandboxaq
Why So Many Drugs Fail in Phase 2 & 3 | Jack Hidary at the Cures Conference  @sandboxaq
Uploaded March 2026 | Updated September 2026, 2 weeks ago
It takes ~10 years to develop a drug — and nearly 85% fail in clinical trials.

But what if we could rescue some of those failed drugs?

In this clip from the Cures Conference, Jack Hidary, CEO of SandboxAQ, explains how physics-based AI can analyze severe side effects, identify which patient subgroups are impacted, and help companies redesign trials instead of shelving promising therapies.

AI isn’t just accelerating discovery. It’s reducing costly late-stage failure.

Watch the full interview here: youtu.be/T35wzsZVsM0

#sandboxaq #lqms #aqbiosim
Why So Many Drugs Fail in Phase 2 & 3 | Jack Hidary at the Cures ConferenceWhy Your Heart Beats: It’s Actually Electricity | Fast FAQts with Brian CottleHow AI is Revolutionizing Catalyst Discovery 🧪 | AQCat Explained Part 1/4AI vs Machine Learning: What’s the Difference? | Bayesian Approach Explained Part 1/4How Quantum Computing Is Forcing a Global Security Shift | Voices of Davos 2026 |Tom PattersonHow Are Quantum Systems Measured? (Part 3/3)Entanglement: Part 4The Future of Drug Development: Large Quantitative ModelsBeyond LLMs: The Next Era of AI, Quantum & Energy | Voices of Davos 2026 | Edwin WangSuperposition: Part 3From the Trading Floor to Deep Tech: Taking Career Leaps with Luca Ferrara | fAQ podcast S3 E8Retrieval Augmented Generation (RAGs): Part 4
SandboxAQ |

Why So Many Drugs Fail in Phase 2 & 3 | Jack Hidary at the Cures Conference

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER